MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced the direct-to-consumer launch of its beta version wellness product, the FOXO Longevity Report™.
The FOXO Longevity Report combines state-of-the-art epigenetic biotechnology, artificial intelligence, and proprietary algorithms to produce longevity and wellness indicators developed from rich epigenetic datasets. Using microarray technology to analyze saliva samples for epigenetic information, the report examines nearly one million sites across the epigenome. This expansive analysis yields a more accurate and user-friendly snapshot of an individual's current health status compared to traditional genetic methods, such as whole genome sequencing.
"The launch of our direct-to-consumer Longevity Report represents the next stage in FOXO's evolution and expands on our successes in the insurance market," said Tyler Danielson, interim-CEO and Chief Technology Officer at FOXO. "We're thrilled to provide a more direct and personalized product offering to help people live their best lives through cutting-edge technology. Our report provides individuals with valuable insight and actionable strategies to improve their health and wellness."
The Longevity Report assesses an individual's health and scores users across four categories: metabolism, inflammation, cardiovascular, and indulgences (smoking and alcohol). Each category includes a score of an individual's health status and evidence-based recommendations to help improve their wellness.
"At FOXO, we're committed to helping people live better, live longer, and optimize their healthspan," said Danielson. "Our Longevity Report is just the beginning. We plan to continue developing innovative solutions that leverage the latest technology to help improve health outcomes for individuals and communities."
FOXO is committed to advancing its mission of developing products and services that provide personalized health assessments related to longevity and aging. Leveraging some of the largest epigenetic data sets in the world, FOXO is actively collaborating with leading researchers from across the country to deepen its understanding of epigenetic patterns across varying ages, tissues, and diseases, with the ultimate vision of helping people improve and optimize their health span and lifespan.
The FOXO Longevity Report (beta) is now available for purchase through FOXO's website. Individuals can order their reports and provide a saliva sample for analysis. Within a few weeks, they will receive personalized reports and recommendations for improving their health and wellness. In addition to receiving the Longevity Report, early adopters will be given product upgrades and exclusive insights at no extra cost as updates are released.
To learn more about the FOXO Longevity Report and start your personalized health assessment related to longevity and aging: https://hello.foxolife.com/foxo-longevity-report-sign-up.
About FOXO Technologies Inc. (“FOXO”)
FOXO is a biotechnology company dedicated to improving human health and longevity through the development of cutting-edge technology and product solutions for various industries, including life insurance. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO is committed to leveraging the latest advancements in science and technology to help people live better, longer lives. For more information about FOXO, visit www.foxotechnologies.com.
This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by the management team of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,” “plan,” project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk of changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; (ii) the ability to implement FOXO’s business plans, forecasts, and other expectations; (iii) the ability to obtain financing if needed; (iv) the ability to maintain its NYSE American listing; (v) the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; (vi) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; (vii) the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and (viii) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO’s prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.